New RCT explains why ‘MagTotal’ is favourable method for health practitioners

When adopting a new technology, it’s important to get buy-in from across the multidisciplinary team. A recent study in JAMA Surgery has found that adopting Magseed and Magtrace does just that by providing user satisfaction across the board.

Published on 27 December 2023the study from Pantiora, Jazrawi et al asked Surgeons, Radiologists and Theatre Coordinators to rate their experiences with both the ‘MagTotal’ approach (Magseed and Magtrace) and guidewire and tracer. The differences between the two were considerable...  

“Satisfaction was higher with the paramagnetic marker across all disciplines, with the difference being more pronounced for surgeons and coordinators.”Pantiora, Jazrawi, Hersi et al (2023)

Reduced operative time and localization failures = Increased HCP satisfaction

 Here are just some of the ways that time and efficiency were realised for the ‘MagTotal’ approach:

  • Magseed time-to-excision was significantly shorter (longest surgery 22 mins vs 30 mins for wire).
  • Total operative time for Magseed was also shorter, creating time for additional cases.
  • The wire had a 10.1% localization failure rate (1.9% for Magseed). In most failed cases, the tumor was identified due to the signal and brown node staining from the SPIO at the injection site.

Combined with the benefits of removing the need for nuclear medicine, the cost and efficiency savings of this approach begin to add up.

Added to that, feedback from the health care professionals implementing the technologies was overwhelmingly positive.

Theatre coordinators and surgeons in particular found the Magseed approach to be a significant upgrade, while Radiologists determined it to be non-inferior.

Magnetic combination “relieves the health care system”

This new study provides concrete evidence that combining Magseed and Magtrace in the same surgical procedure - otherwise known as MagTotal - can provide a highly effective method for the localization and removal of breast cancer.

Want to find out more?

>> Read the full paper here

>> Enquire about adopting the full Sentimag platform